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Review Article
Parasite-driven pathogenesis in Trypanosoma brucei infections
L. J. MORRISON
Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and
Life Sciences, University of Glasgow, Glasgow, UK
SUMMARY
Trypanosomes are protozoan parasites of medical and veter-
inary importance. It is well established that different species,
subspecies and strains of trypanosome can cause very differ-
ent disease in the mammalian host, exemplified by the two
human-infective subspecies of Trypanosoma brucei that
cause either acute or chronic disease. We are beginning to
understand how the host response shapes the course of the
disease and how genetic variation in the host can be a factor
in disease severity, particularly in the mouse model, but until
recently the role of parasite genetic variation that deter-
mines differential disease outcome has been a neglected
area. This review will discuss the recent advances in this
field, covering both our current knowledge of the T. brucei
genes involved and the approaches that are leading towards
the identification of T. brucei virulence genes. Finally, the
potential for using parasite genotype variation to examine
the evolutionary context of virulence will be discussed.
Keywords innate immunity, nagana, pathogenesis, sleeping
sickness, trypanosome
INTRODUCTION
Trypanosomes are single-celled protozoa, transmitted by
tsetse flies (Glossina spp.) to a wide range of mammalian
hosts. They are of well-documented medical significance
to both humans and livestock (1,2). It has been a long
established focus of trypanosome research that the genetic
background of the host plays an important part in deter-
mining disease outcome, and this has formed the basis of
a formidable body of work aiming to define the genetic
basis in both murine and bovine hosts behind either sus-
ceptibility or relative resistance to infection (termed ‘try-
panotolerance’) (3,4). However, an increasing focus of
research is how the genetic background of the parasite can
also have a significant influence upon the outcome of
infection. This is obviously not a new topic for study, as it
has long been recognized that there are virulent and less-
virulent strains of parasite. Indeed, the human-infective
subspecies of Trypanosoma brucei, Trypanosoma brucei
gambiense and Trypanosoma brucei rhodesiense are classi-
cally described as causing very different diseases, with
T. b. gambiense causing chronic infections and T. b. rho-
desiense resulting in acute and severe disease (5). However,
although trypanosome strain variation has long been
acknowledged as an influence upon disease progress, rela-
tively little attention has been focused upon the genes or
gene products in trypanosomes that are responsible for
driving disease in the host towards severity or otherwise.
It seems clear that to produce a holistic model of the
host–parasite interactions that determine infection and
disease dynamics, the evident ability of the parasite to
modulate these outcomes must be incorporated (6,7).
Recent research has started to shed light on trypanosome
virulence as a selective and a selected trait and has begun
to identify trypanosome genes and gene products that are
virulence factors driving disease outcome. This review will
concentrate upon those studies that give particular insight
into how different trypanosome strains are able to cause
different disease outcomes and will highlight potential vir-
ulence factors that have been identified to date. How the
host specifically responds to trypanosome infections is well
covered elsewhere (7–9), including in this issue (see Magez,
Namangala and Bucheton), and this will only be discussed
with respect to how parasites may be influencing the host
response.
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What do we mean by a ‘virulent’ trypanosome? This term
has been used to describe several different phenotypes and
so it is important to define these. In principle, one can
consider three broad descriptors: (1) the level of parasita-
emia and the prepatent period, with virulent strains being
those that give a high parasitaemia and short prepatent
period, (2) transmission efficiency by the vector, with viru-
lent strains being those that are transmitted rapidly and
give high levels of vector infection, and (3) the level of
pathology in the host species (anaemia, organomegaly, tis-
sue penetration, etc.), with virulent strains inducing more
severe disease as measured by these parameters. It is
uncertain whether these different expressions of virulence
are facets of the same phenotype or are distinct but inter-
related phenotypes. Intuitively, the latter seems the most
likely with different parasite gene products being responsi-
ble. Considering a strain that grows quicker than another,
this may indeed contribute to more severe disease, but
there is often not an absolute correlation between parasite
numbers and severity of pathology (10,11). Growth, par-
ticularly in trypanosomes, is also a phenotype that can
rapidly alter through both in vivo and in vitro passage, and
this instability of phenotype in laboratory conditions can
make it an unreliable measurement in terms of strain-spe-
cific virulence (12) (although this does not mean that
growth cannot inform per se regarding pathogenesis, e.g.
by examining the basis of growth rate variants isolated
from the field). Because of the flexibility of the growth
phenotype in trypanosomes, identifying any genetic basis
behind it is likely to prove difficult. An added complica-
tion is that parasites continuously passaged in mice, and
in all likelihood those that are continuously grown in cul-
ture, become ‘monomorphic’ and lose the ability to differ-
entiate in a density-dependent manner to the short stumpy
life cycle stage (13,14). In the light of this, it is obvious
that these parasites will be ‘virulent’, as their lack of self-
limiting differentiation will allow continuous exponential
growth, and in the mouse model, inevitably rapid death.
Therefore, it is essential to use pleomorphic trypanosomes
if a realistic model of the disease process is to be analysed.
In any case, the situation is often more complex than a
simple growth phenotype (15), and perhaps the more
interesting and informative scenario is where one strain
causes more severe disease than the other, despite having
similar growth rates. In these instances, the phenotype can
be measured and the contribution of each parasite strain
to host phenotypes can be quantified, as well as providing
a comparative approach towards identifying the genetic or
proteomic basis for the differences. An additional compli-
cation in a number of pathogen researches is the use of
model hosts (mice) as opposed to ‘natural’ hosts (e.g. live-
stock or humans for trypanosomes). However, it is becom-
ing increasingly clear that the mouse provides a crucial
experimental tool to dissect the processes that are central
to pathogenesis in trypanosomiasis (16,17). The post-geno-
mic era has allowed a move away from the focus on a sin-
gle gene, towards a more holistic identification of
pathways, their connections and the common processes
between different host models that may prove crucial to
our fuller understanding of how the disease manifests and
progresses in trypanosomiasis.
The incorporation of parasite virulence into disease
models has proved useful for the understanding of infec-
tion dynamics in several other protozoan parasites. In par-
ticular, the examination of the relative contribution of
parasite virulence towards disease has been examined in
Plasmodium species (18–20), where the implications of par-
asite virulence and the selective pressures that result in vir-
ulence are starting to be understood and examined at both
the individual and population levels (21). Different species
of Leishmania have tropism for different host tissues that
results in very different patterns of pathology, and this has
been investigated both at the genomic level (22) and with
respect to specific genes that are potentially responsible
(23). However, it must be stressed that we do not know if
these are strain- or species-specific traits. Perhaps one of
the most elegant demonstrations of the use of genomic and
post-genomic tools to identify a parasite genetic basis of
virulence has been carried out for Toxoplasma gondii,
where using a forward genetic approach a serine-threonine
kinase was identified as a virulence factor (24,25), the role
of which has since been confirmed in differential virulence
in field isolates (26). The impact of this gene during infec-
tions in the natural hosts (i.e. cat and man) is perhaps the
final piece of this picture remaining to be analysed. These
approaches have until recently not been comprehensively
used to analyse trypanosomes, in which the understanding
of the contribution of the parasite genetic background to
disease remains scanty by comparison.
We are beginning to understand how genetic variation
in the trypanosome arises, whether it is by clonal or sexual
reproduction, and are able to measure the levels of genetic
diversity within and between geographically distinct foci of
trypanosome disease. The role of sexual recombination
and genetic diversity does vary in terms of species; for
example, T. vivax seems to multiply clonally and remains
relatively similar within a focus, whereas T. congolense
undergoes frequent sexual recombination and is genetically
diverse even within a population from a single endemic
focus (27,28). The situation in T. brucei is more complex,
and while the limited number of studies suggest that field
populations in nonhuman hosts (e.g. cattle) undergo
frequent mating and are genetically diverse, the human-
infective subspecies undergo genetic exchange rarely and
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are genetically less diverse, at least within geographic foci
(29–32). Understanding the dynamics of gene flow within
populations is important to further comprehend how traits
spread spatially and temporally. The level of genetic varia-
tion and differentiation that has been described will
undoubtedly contribute to phenotypic variation, but we
know relatively little about how genetic variation trans-
lates into phenotype differences in T. brucei, and it is this
link between genotype and phenotype in the parasite that
is the focus of this review.
This review will consider three aspects of virulence from
the parasite perspective, firstly strain-specific variation in
virulence, secondly identified candidate virulence genes
and thirdly the importance of virulence in epidemiological
and evolutionary contexts.
IDENTIFIED STRAIN-SPECIFIC GENE EFFECTS
IN T. BRUCEI
Strain variation in virulence
The analysis of differing disease outcome with respect to
trypanosome strain or genotype has been examined histor-
ically using basic pathology parameters, e.g. (33,34), which
provided useful descriptions of strain-specific differences
in pathology. More recent studies have begun to elucidate
the trypanosome factors responsible for these different
pathologies and have addressed the problem using differ-
ent approaches. Virulence variants of T. b. gambiense
(tested in mice) from the same focus of disease have been
analysed using proteomics to identify components in the
trypanosome secretome, with the rationale that secreted
trypanosome proteins may be responsible for the key
host–parasite interactions influencing disease outcome
(11). This study identified both proteins that were differen-
tially expressed between the strains, as well as proteins
that were expressed only in one strain or the other. The
analysis of the host response suggested that it was macro-
phage activation that was key to the virulence status of
the parasite. The causative proteins in this instance, and
whether it is differential or absolute expression of one or
several factors, remain to be elucidated however.
More detailed insight into a specific host–parasite inter-
action has been gained using an experimental model of the
blood–brain barrier, where it has been demonstrated that
different strains of trypanosome are able to cross the
endothelial barrier with different efficiencies; IL1852
(a T. b. rhodesiense isolate) is able to cross with much
greater efficiency than TREU927 (T. b. brucei) (35). The
basis of this has been demonstrated to be at least in part
because of a secreted cathepsin L cysteine protease,
brucipain (36), and is because of alteration of intracellular
calcium concentrations in the endothelial cells that is
mediated by brucipain (37), perhaps via protease-activated
receptors on the host cell (38). Although this has been sug-
gested to provide the human-infective trypanosomes in par-
ticular with a mechanism for brain tissue tropism, only one
strain of human-infective parasite has thus far been used.
Despite this, the study provides clear evidence for a
virulence factor. The basis of this differential virulence was
correlated with differential activity of brucipain in the sec-
retome, with the T. b. rhodesiense lysate having 10-fold
greater protease activity than that of T. b. brucei (37). The
basis behind this differential activity is an important issue
to address: is the protease itself more active (is this because
of a strain-specific polymorphism, for example) or does the
T. b. rhodesiense strain secrete more of the protease – as a
multicopy gene do gene copy numbers vary between strains
– or is it variation at the individual gene expression level?
There is some evidence for the latter scenario, as when
expression of brucipain was reduced using RNA interfer-
ence, the ability of T. b. brucei to cross an in vitro endothe-
lial layer was inhibited by 50% (36). Given the potential
importance of this virulence factor, these questions are a
significant area of interest for understanding strain-specific
virulence. Although previous attempts to use the T. congo-
lense orthologue, congopain, as an antidisease vaccine can-
didate in cattle met with a degree of success (39),
T. congolense is largely an intravascular parasite, whereas
T. brucei is extensively extravascular, and therefore it could
be postulated that virulence factors such as brucipain in
T. brucei will consequently have more disseminated and tis-
sue-specific effects (as an obvious example, involvement of
the brain and sleeping sickness).
Forward genetics approach to trypanosome virulence var-
iation
In our laboratory, we have been using a forward genetic
approach to identify regions of the Trypanosoma brucei
genome that contain genes that are responsible for differ-
ential pathogenesis. This provides an unbiased approach
to identify the causative gene(s), because no a priori
hypothesis of putative responsible factors needs to be
invoked. Two strains of T. brucei form the basis of these
studies, TREU927 (the genome reference strain) and
STIB247. These strains differ inherently in the pathology
that they induce during infections in mice (15). It should
be emphasized that the differences are not because of the
parasites simply having different growth rates, and the
strains used in our study were matched for passage num-
bers and crucially were both pleomorphic parasites that
have maintained the key characteristics of ‘wild-type’ try-
panosomes (differentiation to the short stumpy life cycle
L. J. Morrison et al. Parasite Immunology
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stage and tsetse transmissibility). Inbred (BALB ⁄ c) mice
infected with either STIB247 or TREU927 displayed sig-
nificantly different pathology, with TREU927 infections
resulting in more severe anaemia, reduced reticulocytosis,
a less severe degree of splenomegaly, and increased IFNc
and IL-10, but reduced IL-12, levels compared to STIB247
infections (when measured up to day 12 post-infection).
Gene expression analysis of host cells in the spleen at day
10 post-infection was undertaken (15), and pathway analy-
sis revealed that the main processes that were differentially
regulated between the infections were Liver X receptor
activation, IL-10 signalling and alternative macrophage
activation. It should be noted that pathways linked to the
acquired immune response were significantly upregulated
in both infections, but to the same degree, and it was
therefore considered unlikely that they were responsible
for the differential pathogenesis. These data combine to
suggest that the innate immune response is being differen-
tially activated by the parasite strains and therefore that
there must be a significant genetic basis in the parasite for
this phenomenon.
These two strains had previously been used to generate
the first genetic map of T. brucei (40). The availability of
this and accompanying resources allowed the use of a clas-
sical forward genetic approach to analyse the inheritance
of the pathogenesis phenotypes in infections with the F1
progeny clones that had been generated and incorporated
in the genetic map (41,42). Infections were undertaken in
BALB ⁄ c mice with the progeny clones and the phenotypes
measured as in Morrison et al. (2010). Quantitative trait
loci (QTL) analysis was undertaken to identify regions of
the genome that contained genes responsible for the mea-
sured traits (43). A QTL on T. brucei chromosome 3 (LOD
score = 7Æ2), which contributed approximately 65% of the
variance observed in both splenomegaly and hepatomegaly,
was the major finding of the study. The QTL encompasses
383 genes, and so further work is required to identify the
gene(s) responsible within the QTL interval. This can be
approached from several angles: firstly, fine mapping to
reduce the interval boundaries by using additional infor-
mative markers [microsatellites and single nucleotide poly-
morphisms (SNPs)] and through the isolation of further
progeny clones with informative crossovers; secondly, a
more defined phenotype will provide more information –
i.e. the measurements used (spleen and liver weight) can
undoubtedly be influenced by multiple mechanisms and
pathways, but by using, for example the expression levels
of key genes in the implicated pathways (15), this may give
much cleaner segregation patterns and significant linkage
to a smaller region of the chromosome; and thirdly by
identifying candidate genes [for example, by SNP analysis
– the gene must be heterozygous in TREU927 to be infor-
mative in this cross (15)]. In addition, a second, less signifi-
cant, locus on chromosome 2 contributed to splenomegaly,
hepatomegaly and reticulocytosis. The importance of these
findings is that this provides an avenue to identify genes in
the trypanosome genome that are responsible for influenc-
ing the host immune response and determining the severity
of infection, and this work is ongoing. These findings have
parallels with field data, where genotypic differences in
Ugandan T. b. rhodesiense isolates correlated with differing
severity of disease in sleeping sickness patients (44,45) –
although this conclusion does require further confirmation,
because of the inherent difficulty of eliminating host varia-
tion as a confounding factor.
CANDIDATE VIRULENCE FACTORS
It seems clear from studies into how the host responds to
trypanosome infection that several facets of the innate
immune response are crucial in determining disease out-
come. In particular, the polarization of the immune
response, whether it is IFNc or IL-10 dominated (46,47),
or whether alternative or classical macrophages are pre-
dominant (48,49), together with the role of regulatory
T cells (50–52), seem to be crucial in shaping the severity
and duration of the pathology observed. Within this, a
broad conclusion can be drawn from studies using hosts
of differing inherent susceptibility or tolerance to trypano-
somes (10,53,54), as well as our study involving different
parasite strains (15), that it is the relative timing of these
processes that ultimately determine whether the pathology
will be severe or not. Therefore, any parasite gene or gene
product that influences the direction in which the activa-
tion of the immune response progresses is a candidate vir-
ulence factor, and particularly if the expression or activity
of the candidate gene varies between strains. As these pro-
cesses largely involve effector molecules, and tend to be
downstream of regulatory processes, it seems reasonable to
assume that it will be parasite-based differences in activa-
tion at the recognition or regulatory stage, for example
pattern recognition receptors such as Toll-like receptors,
that initiate and are responsible for the direction of polari-
zation of downstream effector arms of the response. As
yet, the parasite products that directly affect the features
of the host immune response have not been characterized
for any strain-specific ability to cause different disease out-
comes, but several have been implicated as virulence fac-
tors per se (55) at the single-strain level. For example, in
addition to the cysteine peptidase described earlier, other
peptidases have been identified that also retain activity in
the serum of the infected host, and which therefore may
be able to effect host processes directly (56,57). Perhaps
the best characterized immunostimulatory parasite product
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is the variant surface glycoprotein (VSG), which is the
mainstay of the trypanosome’s remarkable system of anti-
genic variation (58–60). Aside from their well-character-
ized role as changing cloaks that disguise the trypanosome
from the host acquired immune response, the glycosyl-
phosphatidylinositol anchors that tether the VSG to the
parasite surface membrane have been shown to be a key
factor in immune response activation; this is particularly
the case with soluble VSG, which is actively cleaved by
parasite phospholipase-C and released into the extracellu-
lar medium. Both the glycosylinositolphosphate (on the
shed VSG) and dymyristoylglycerol (membrane bound)
moieties have been implicated in shaping the immune
response to trypanosomes (61–63). How the VSG and
associated moieties could result in differential disease out-
come based on strain-specific differences is unclear, but it
could be that different strains exhibit structural differ-
ences, including the possibility of variable polysaccharide
side chains, or different rates of VSG shedding, which
may lead to variable activation of host receptors. Intrigu-
ingly, a trypanosome protein that directly modulates the
host’s immune response, termed the trypanosome-suppres-
sive immunomodulating factor (TSIF) was recently
described (64). The protein was suggested to be a surface-
bound membrane protein, inferred by the fact that anti-
body raised against recombinant TSIF-stained fixed cells,
but not live cells, and this was confirmed using immuno-
precipitation from lsyates of parasites that were surface-
labelled with I125. Recombinant TSIF induced TNFa and
NO production from macrophages in vitro and reduced
type 2 immune response-mediated pathology in vivo. This
suggests that TSIF activates TNFa-producing classically
(M1) activated macrophages. Although this seems appar-
ently paradoxical at first glance, as type 1 immune
responses and IFNc production are correlated with con-
trol of parasite numbers (46), the authors suggested that
the activity of TSIF is consistent with it playing a role in
the immunosuppression that is characteristic of trypano-
some infections (65,66). An intriguing prospect would be
to analyse TSIF from different strains of trypanosome
and characterize any differential effect.
Although we are increasing our understanding of the
host immunological forces that respond to trypanosome
infection and shape the disease process, it is clear that in
this context the contribution of the trypanosome is less
well understood. The examples described here demonstrate
that candidates have been identified for parasite products
that influence the host response, but most of these have
not been examined with respect to the range of disease
patterns caused by different strains of the parasite. Addi-
tionally, commonalities from several studies, for example
the activation status of macrophages as being a crucial
indicator of the virulence of a trypanosome strain
(11,15,64), suggest that in addition to providing insight
into how the parasite causes disease, parasite virulence
variation could well prove to be an invaluable tool for dis-
secting the host response to trypanosome infection.
IMPORTANCE AND EPIDEMIOLOGICAL
IMPLICATIONS
A crucial perspective when considering virulence is why do
parasites evolve to become virulent or less virulent – what
are the selective pressures that drive parasites to become
more or less pathogenic? One obvious variable that has
been studied is the influence of different host genetic back-
grounds, as has been suggested as a key factor for natural
infections with T. congolense (67). This has been proposed
as a reason why virulent parasite strains of T. congolense
emerge in regions where different host species predominate
in Zambia – relatively susceptible cattle populations and
relatively resistant wild animals presenting different selec-
tive pressures on parasite virulence (67). It seems clear
that there will be a two-way relationship in this context,
with virulence of the parasite and tolerance of the host
imposing selection, the selective pressure being dependent
upon the status of each participant. An area that has been
extensively studied in Plasmodium is the relationship
between parasite virulence and transmission to the vector,
and the evolutionary trade-offs between harm to the host
and overall transmission fitness (19). Put simply, the ulti-
mate objective of a mammalian infection from the try-
panosome perspective has to be successful transmission
onwards to the tsetse vector. Recent work has postulated,
based on data obtained from studying the protozoan para-
site Ophyrocystis elektroscirrha of the monarch butterfly,
that the ‘optimum’ virulence state of a parasite in terms of
balancing harm to the host with successful transmission is
intermediate virulence (68). However, this is again looking
at one side of a coin – if different selective pressures from
the host are considered, then the optimum virulence of the
parasite for eventual transmission becomes relative to the
susceptibility ⁄ resistance of the host. This was confirmed in
a follow-up study, where the virulence status rankings for
O. elektroscirrha genotypes differed between host geno-
types, and the authors concluded that it is crucial to con-
sider genotype–genotype interactions when examining the
evolution of virulence in a larger context (69). Therefore,
it becomes apparent that the pathogenic status of a para-
site becomes intrinsically linked to the selective pressures
that are imposed by the genetics of the other integral com-
ponents of the holistic life cycle. With vector-borne para-
sites, this includes the often forgotten potential selective
effects within the vector, as has been proposed in Theileria
L. J. Morrison et al. Parasite Immunology
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and analysed in Plasmodium, where genetic bottlenecks in
the arthropod vector have been suggested to play a role in
the pathological outcome in the mammal (70,71). Similar
selective bottlenecks have recently been demonstrated to
occur in the tsetse vector with T. brucei (72). An addi-
tional level of complexity that needs to be considered is
the influence of mixed infections, whether with more than
one species of trypanosome or other parasite (73) or from
co-infection with different strains of the same parasite
(74,75) – both of these scenarios undoubtedly occur widely
in the field. Thus, to understand the evolution of patho-
genesis ⁄ virulence in trypanosomes, one must do so in an
integrated fashion, incorporating genetic and phenotypic
variation in the trypanosome, the mammalian host and
the tsetse vector, otherwise any findings will only have rel-
evance for the particular genotype–genotype interaction
being considered. These aspects of the relationship
between host, vector and parasite have been relatively
understudied in trypanosomes, but the availability of
defined trypanosome strains, in addition to the well-char-
acterized mouse strains, means that the tools are now
available to address these questions.
CONCLUSIONS
How the parasite itself shapes the course of disease is a
relatively neglected but important area of research with
respect to trypanosomes. Identifying how virulent strains
cause clinical signs will increase our understanding of how
disease progresses, addressing a fundamental question of
trypanosome biology, and provide the potential to develop
antidisease strategies. The post-genomic tools now avail-
able provide an incredible opportunity to begin to under-
stand these processes. The field is moving on from single-
gene studies towards focussing on identifying regulatory
genes and processes, by taking advantage of technological
advances such as RNAseq, the ability to visualize in vivo
and live cell–cell interactions (76), multiple pathogen and
host genome sequences, the impending genome sequence
of the tsetse vector, in silico modelling, and the increasing
number of gene knockout mice available. Therefore, the
opportunity now exists to incorporate these approaches in
a more systems-based manner, enabling us to understand
more completely the bigger picture and the unravelling of
how the key host–parasite interactions drive disease. Cru-
cially, the introduction of parasite genetic and phenotypic
variation into existing disease models of trypanosomiasis
will provide experimental resources to allow a deeper
understanding of both host and parasite determination of
disease outcome and the addressing of larger evolutionary
questions.
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